Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMABᅢᄁ¬ダᅡᄁ, the Companyᅢᄁ¬ツᆲ¬トᄁs proprietary antibody drug discovery platform. Its lead immuno-oncology drug candidate, APX005M, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.